| abstract |
FIELD: biotechnology. n SUBSTANCE: invention relates to biotechnology, specifically to production of insulin derivatives containing additional disulphide bonds, and can be used in medicine. Two cysteine substitutes are added to human insulin, said substitutes selected from a group comprising A10C, B2C; A10C, B3C; and A10C, B4C and side chain, which is bonded to N-end of insulin or epsilon amino group of lysine residue in insulin. n EFFECT: invention enables to produce a human insulin derivative having a prolonged profile in comparison with native human insulin. n 13 cl, 4 dwg, 114 ex |